Evotec Signs Two Significant Contracts with Roche

Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that it signed two significant service contracts with Roche. These contracts build on the companies' long-standing relationship and Evotec's positive contribution to Roche's discovery projects. They extend the global medicinal chemistry agreement signed in May 2004 for a further 12 months and its medicinal chemistry collaboration in oncology, signed in October 2003, for an additional 2 years.
 
In the global medicinal chemistry agreement a dedicated team of chemists from Evotec supports all of Roche's European and US research sites in the design and synthesis of high quality compounds for lead finding and optimisation programmes. In the medicinal chemistry oncology collaboration, both companies aim to identify and develop a clinical lead candidate for a priority target within Roche's oncology research.
 
Dr Mark Ashton, Executive Vice President Business Development Services at Evotec, said: "We are extremely proud to have been working with Roche since 2001 as one of their preferred partners. These significant research programmes announced today are of particular importance for Evotec. They emphasise our world leading expertise in medicinal chemistry and the continued trust of our partner Roche. We look forward to continuing to work closely with scientists at Roche for a number of years."

Contact: Anne Hennecke, Director, Investor Relations & Corporate Communications, Evotec AG, Phone: +49-40-56081-286, anne.hennecke@evotec.com
Contact: Anne Hennecke, Director, Investor Relations & Corporate Communications, Evotec AG, Phone: +49-40-56081-286, anne.hennecke@evotec.com